EP0801059A1 — Indole derivative
Assigned to Sumitomo Pharma Co Ltd · Expires 1997-10-15 · 29y expired
What this patent protects
An indole derivative of the formula: wherein R 1 is lower alkoxy, lower alkoxycarbonyl-lower alkoxy, carboxy-lower alkoxy , lower alkoxycarbonyl, phenyl-lower alkoxy, lower alkyl being optionally substituted by hydroxy, di-lower alkylaminosulfonyl, etc., R 2 is hydrogen, …
USPTO Abstract
An indole derivative of the formula: wherein R 1 is lower alkoxy, lower alkoxycarbonyl-lower alkoxy, carboxy-lower alkoxy , lower alkoxycarbonyl, phenyl-lower alkoxy, lower alkyl being optionally substituted by hydroxy, di-lower alkylaminosulfonyl, etc., R 2 is hydrogen, halogen, lower alkoxy, lower alkoxycarbonyl-lower alkoxy, carboxy-lower alkoxy, etc., R 3 is hydrogen or lower alkyl, R 4 is halogen or trifluoromethyl, R 5 is lower alkyl, or a salt thereof, these compounds being potent β 3 -adrenergic receptor-stimulating agent with excellent adrenoceptor selectivity, and being useful in the prophylaxis or treatment of obesity or diabetes mellitus.
Drugs covered by this patent
- Velsipity (Etrasimod Arginine) · Pfizer Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.